Immuneering CORP 8-K filings

Immuneering Corporation announced its second quarter 2026 financial results, highlighting progress in its Phase 3 MAPKeeper 301 trial for pancreatic cancer and a cash runway extending into 2029.

Immuneering Corporation announces the appointment of Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026.

Immuneering Corporation successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of two directors and the appointment of its independent auditor.

Immuneering Corporation announced updated Phase 2a clinical trial results for atebimetinib in first-line pancreatic cancer, showing a 17.3-month median overall survival.

Immuneering Corporation announced first quarter 2026 financial results, highlighting progress in its atebimetinib clinical trials for pancreatic cancer and a cash runway extending into 2029.

Immuneering Corporation announced positive Phase 2a data for atebimetinib in pancreatic cancer, reporting 64% overall survival at 12 months, alongside full-year 2025 financial results and an extended cash runway into 2029.

Immuneering Corporation announced updated interim Phase 2a clinical trial data for atebimetinib in first-line pancreatic cancer, demonstrating significantly improved overall survival compared to standard of care.

Immuneering Corporation announced strong third-quarter 2025 financial results and significant clinical advancements, including extraordinary overall survival data for atebimetinib in first-line pancreatic cancer and extended cash runway into 2029.

Immuneering Corporation announced a public offering of 18.96 million shares and a concurrent $25 million private placement with Sanofi's subsidiary, extending its cash runway into 2029.

Immuneering Corporation announced a $25 million private placement from Sanofi, contingent on a $75 million public offering, alongside positive interim Phase 2a data for atebimetinib in pancreatic cancer.

Immuneering Corporation announced a $25 million private placement to fund its oncology pipeline, following promising Phase 2a pancreatic cancer data.

Immuneering Corporation reported positive second-quarter 2025 financial results and significant clinical progress for its lead drug candidate, atebimetinib, in pancreatic cancer.

Immuneering Corporation announced encouraging interim Phase 2a clinical trial results for its MEK inhibitor atebimetinib in combination with mGnP for first-line pancreatic cancer, showing an 81% disease control rate and a 39% overall response rate, with plans for a pivotal trial in 2026.

Immuneering Corporation announced the results of its Annual Meeting of Stockholders held on June 13, 2025, where shareholders elected three Class I directors and ratified RSM US LLP as the independent registered public accounting firm.

Immuneering Corporation announced encouraging Phase 2a trial data for IMM-1-104, a clinical trial supply agreement with Regeneron, the appointment of a new Chief Medical Officer, and an extended cash runway into 2026.

Immuneering Corporation announced positive data from its Phase 2a trial of IMM-1-104, a clinical trial supply agreement with Regeneron, the appointment of a new Chief Medical Officer, and an extended cash runway into 2026.

Immuneering Corporation reported a 50% overall response rate in a Phase 2a trial for pancreatic cancer and raised $13.7 million through an equity offering.

Immuneering Corporation reported positive interim results from its Phase 2a trials for IMM-1-104 in pancreatic cancer and initial data for IMM-6-415 in advanced solid tumors.

Immuneering reported positive initial clinical trial data for IMM-1-104 in pancreatic cancer, along with third quarter 2024 financial results and business updates.

Immuneering Corporation has amended its previous 8-K filing to announce the appointment of Dr. Thomas J. Schall to the Compensation Committee, effective October 1, 2024.

Immuneering Corporation reported encouraging early results from its Phase 2a trial of IMM-1-104 in combination with chemotherapy for first-line pancreatic cancer, showing a high disease control rate.

Immuneering Corporation announced its second quarter 2024 financial results, highlighting progress in clinical trials and a recent FDA Fast Track designation.

Immuneering Corporation held its annual meeting on June 12, 2024, where stockholders elected two Class III directors and ratified the appointment of RSM US LLP as the company's independent auditor.

Immuneering Corporation has repriced stock options for eligible employees and service providers to $3.01 per share, aiming to boost retention and motivation.

Immuneering Corporation announced positive topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 and provided a business update for the first quarter of 2024.

Immuneering Corporation has initiated the Phase 2a portion of its clinical trial for IMM-1-104 and reported positive topline results from the Phase 1 portion, showing promising safety and efficacy data.

Immuneering Corporation reported its fourth quarter and full-year 2023 financial results, alongside key clinical trial updates for its lead drug candidates.

Immuneering Corporation's Board of Directors has adopted amendments to the company's bylaws, primarily focusing on universal proxy rules and enhanced procedures for stockholder meetings.